There is no standard treatment for radiation dermatitis. In this study, the investigators have designed novel ROS-scavenging nanoenzymes and aim to evaluate their effectiveness in preventing radiation dermatitis in patients with head and neck cancer.
Patients with a pathological diagnosis of non-metastatic head and neck malignant tumors;
Patients deemed suitable for high-dose radiotherapy, either as a primary treatment or as postoperative treatment following surgical resection.
Eastern Cooperative Oncology Group performance status of >2;
Pre-existing skin rash, ulceration or open wound in the treatment area;
Inflammatory or connective tissue disorder of the skin;
History of head and neck radiotherapy.
Parallel
ROS-scavenging Nanoenzymes
DrugROS-scavenging nanoenzymes are applied to the treatment area, once daily during radiotherapy.
Standard of care
BehavioralStandard of care
The incidence of grade 2 or higher radiation dermatitis
Patients are assessed weekly for radiation dermatitis by an experienced radiation oncology nurse according to the Radiation Therapy Oncology Group (RTOG) criteria.
The maximum skin toxicity
The maximum grade of RTOG skin toxicity between 0 and 4.
Click on the lead sponsor to view all of their trials.
